stockrow
Saturday 7 November 2026
Export BYSI’s income statement to Excel — free account
BeyondSpring Inc.
BYSI Healthcare Biotechnology
BeyondSpring Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.4 million.
- EPS
- +50.0%
- Free cash flow
- +35.8%
Quarter to June 2026, against a year earlier
0.61
0.02
−3.17%
Follow BYSI
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 24.96% | 35.53% | 5.26% | 2.05% |
+8 more TTM periods Free account |
|
| (29.29%) | (27.53%) | (3.34%) | (2.37%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
160.93% | (594.25%) | (13.46%) | (5.11%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.41) | (0.46) | (0.49) | (0.33) | |
Free Cash Flow |
(16.75) | (18.85) | (19.82) | (13.36) | |
Capital Expenditures |
— | — | (0.05) | (0.08) | |
| Other line items | |||||
Cash ROIC |
56.77% | 83.80% | 173.41% | 185.92% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.04 | 0.03 | 0.01 | 0.13 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
2.51 | 2.47 | 19.65 | 22.21 | |
Depreciation/Fixed assets |
(0.27) | 0.17 | 0.52 | 1.43 | |
Capex/Depreciation |
0.00 | 0.00 | (0.57) | (0.29) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.41) | (0.46) | (0.49) | (0.33) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026